

Anti-Human Endocan/ESM-1 Monoclonal Antibody Clone MEC15 (N-Ter)

Essential Notes

Cat. Number : LIA-1002S

Clone : MEC 15

Size : 20 µg

Formulation : PBS pH 7.4

Storage : -20°C

Immunogen : CHO cell derived affinity purified recombinant endocan

Specificity : human and monkey endocan

Source : mouse

Ig isotype : IgG1

Applications : WB, ELISA, FC

Preparation/source

Endocan/ESM-1 is a 165 amino acid peptide that carries a dermatan sulfate chain. Anti-endocan/ESM-1 antibodies clone MEC15 were produced from a hybridoma resulting from the fusion of mouse myeloma Sp2/0 cells with B cells obtained from mouse immunized with CHO cell derived affinity recombinant endocan (Lassalle et al. 1996; Bechard et al. 2000). They were purified by protein G affinity chromatography.

Formulation

Solution in phosphate buffer saline 1x, pH 7.4

Concentration

The concentration of MEC15 was 1 mg/mL as determined by measurement of protein and mouse IgG concentration.

Purity

Purity > 90%, as determined by SDS-PAGE and as visualized by silver staining.

Specificity & Bioactivity

Specificity is determined by ability to recognize **human and monkey endocan** but not to cross-react with mouse or rat endocan.

Storage

Samples in PBS can be easily aliquoted. They can be stored frozen from -20°C to -80°C. Avoid repeated freeze-thaw cycles.


Applications

Western blot (WB) : Recommended working dilutions were determined to be 1 µg/mL. Optimal dilutions should be determined according sample origins.

ELISA : Recommended working dilutions were determined to be 100 ng/mL, as detection antibody.

Flow Cytometry (FC) : Dilutions as to be figured out according to the cell type of interest.

Other : to be determined.



Immunodetection using the anti-endocan/ESM-1 clone MEC15 of a fully glycosylated endocan (LIP-1101) and of endocan when devoid of a glycosaminoglycan chain.(LIP-1102)

■ Bibliography related to MEC15 Antibody Applications

- Bechard et al. (2000)** Characterization of the secreted form of ESM-1 by specific monoclonal antibodies. *J. Vasc. Res.* 37:417-425.
- Grigoriu et al. (2006)** Endocan expression and relationship with survival in human non-small cell lung cancer. *Clin. Cancer Res.* 12:4575-4582.
- Leroy et al. (2010)** Vascular endocan (ESM-1) is markedly overexpressed in clear cell renal cell carcinoma. *Histopathology* 56:180-187.
- Mikkelsen et al. (2011)** Lower Serum Endocan Levels Are Associated with the Development of Acute Lung Injury after Major Trauma. *J. Crit. Care*: In Press, July 2011.

■ BACKGROUND

Endocan, also known as endothelial cell-specific molecule (ESM-1), was originally discovered by Lassalle and collaborators in endothelial cells (Lassalle et al. 1996). Structurally, endocan is a dermatan sulfate proteoglycan of 50 kDa that is freely circulating in blood (Bechard et al. 2001a; Sarrazin et al. 2010a). Endocan binds CD11a/CD18 integrin (also called LFA-1 for Leukocyte Function-associated Antigen-1) on human leukocytes inhibiting consequently its binding to ICAM-1 and transendothelial migration (Bechard et al. 2001b). Moreover, endocan has been recently described as a biomarker of tip cells (Sarrazin et al. 2010b). The expression of endocan is upregulated by pro-inflammatory molecules such as tumor necrosis factor alpha (TNF α), and pro-angiogenic molecules such as vascular endothelial growth factor (VEGF) and fibroblast growth factor 2 (FGF-2) (Grigoriu et al. 2006; Sarrazin et al. 2006; Maurage et al. 2009). Endocan binds via its dermatan sulfate chain to hepatocyte growth factor/scatter factor (HGF/SF) (Bechard et al. 2001a; Sarrazin et al. 2010b). Elevated blood levels of endocan has been reported in patients with lung and kidney cancers as well as in patients with severe sepsis (Bechard et al. 2001b; Scherpereel et al. 2003; Grigoriu et al. 2006; Scherpereel et al. 2006; Sarrazin et al. 2010b; Leroy et al. 2010). Endocan appears as a pertinent biomarker of endothelial dysfunction (Sarrazin et al. 2010b).

■ Endocan Background Bibliography

- Abid et al. (2006)** Vascular endocan is preferentially expressed in tumor endothelium. *Microvasc. Res.* 72:136-145.
- Bechard et al. (2001a)** Endocan is a novel CS/DS proteoglycan that promotes HGF/SF mitogenic activity. *J. Biol. Chem.* 276:48341-48349.
- Bechard et al. (2001b)** Human ESM-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to ICAM-1. *J. Immunol.* 167:3099-3106.
- Lassalle et al. (1996)** ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. *J. Biol. Chem.* 271:20458-20464.
- Leroy et al. (2010)** Vascular endocan (ESM-1) is markedly overexpressed in clear cell renal cell carcinoma. *Histopathology* 56:180-187.
- Maurage et al. (2009)** Endocan expression and localization in human glioblastomas. *J. Neuropathol. Exp. Neurol.* 68:836-844.
- Sarrazin et al. (2006)** Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker. *BBA Reviews* 1765:25-37.
- Sarrazin et al. (2010a)** Characterization and binding activity of the chondroitin/dermatan sulfate chain from Endocan, a soluble endothelial proteoglycan. *Glycobiology.* 20:1380-1388.
- Sarrazin et al. (2010b)** Endocan as a biomarker of endothelial dysfunction in cancer. *J. Canc. Sci. Ther.* 2:47-52.
- Scherpereel et al. (2003)** Overexpression of endocan induces tumor formation. *Cancer Res.* 63:6084-6089.
- Scherpereel et al. (2006)** Endocan, a new endothelial marker in human sepsis. *Crit. Care Med.* 34:532-537.
- Tsai et al. (2002)** Cloning and characterization of the human lung ESM-1 promoter. *J. Vasc. Res.* 39:148-159.

■ Companion products

- Anti-human endocan/ESM-1 mAb (N-ter) ; clone MEP08 : **LIA-0901**
- Anti-human endocan/ESM-1 mAb (N-ter) ; clone MEC15 : **LIA-1002**
- Anti-human endocan/ESM-1 mAb (N-ter) ; clone MEP21 : **LIA-0902**
- Human recombinant endocan/ESM-1 (50 kDa) : **LIP-1001**
- DIYEK EndoMark H1 (ImmunoAssay against human endocan) : **LIK-1101**

Address : Lunginnov s.a.s, Campus de l'Institut Pasteur de Lille, 1 rue du Pr Calmette, 59000 LILLE, France
Supports & Orders: www.lunginnov.com

Tel: (33) 320 877 211 Fax: (33) 320 877 884